Composition for improving skin barrier or elasticity

Abstract

The present disclosure relates to a composition for improving skin barrier or elasticity. With a significantly superior synergistic effect on improving the skin barrier or elasticity through a specific combination of active ingredients, the composition for improving skin barrier or elasticity of the present disclosure can be effectively used as a functional composition in cosmetics or topical formulations targeting skin tissue.

Description

Composition for improving skin barrier or elasticity

[0001] This application claims priority to Republic of Korea Application No. 10-2024-0027528, filed February 26, 2024, the entire disclosure of which is incorporated herein by reference.

[0002] The present disclosure relates to a composition for improving skin barrier or elasticity.

[0003] The skin protects the body from the external environment and serves as a barrier, preventing internal moisture and beneficial substances from leaking out. Furthermore, it is a vital organ responsible for various physiological functions, such as temperature regulation and excretion. However, skin cell activity can decline and skin condition can worsen for the following reasons.

[0004] Collagen and elastin, found in the dermal layer of the skin, play a significant role in skin composition, providing mechanical strength, connective tissue resistance, maintaining tissue cohesion, and supporting cell adhesion. Collagen is reduced by stress, aging, and photoaging caused by UV exposure. Furthermore, elastin is known to distort its three-dimensional structure after exposure to UV rays due to increased activity of elastase. Consequently, the decrease in collagen or decreased activity of elastin causes skin tissue to become loose and lose elasticity.

[0005] As epidermal cellular function declines, metabolism becomes impeded, and dead skin cells fail to shed properly, leading to excessive accumulation of dead skin cells. In this state, exposure to UV rays can lead to a decline in skin elasticity, resulting in wrinkles. Alternatively, if a sebum barrier fails to form on the epidermis, moisture and sebum secretion decrease, drying out the skin and leading to the formation of wrinkles.

[0006] Sebum, sweat, and cosmetic ingredients can be broken down by skin flora into highly toxic substances, causing skin irritation and inflammation. Furthermore, UV exposure can increase the production of nitric oxide (NO), an inflammatory mediator, in the skin, potentially triggering skin problems. Nitric oxide production is largely driven by iNOS, which is known to be rapidly induced by stimuli such as LPS or cytokines, leading to excessive NO production.

[0007] Reactive oxygen species (ROS), also known as toxic oxygen species, are toxic substances produced in cells by physiological processes such as respiration. They are constantly produced and destroyed, and exist in about 3-5% of the body under normal conditions. These reactive oxygen species include superoxide radicals (O2). - ), hydroxyl radical (HO + ) exist as free radicals (atoms or molecules that do not have paired electrons in their outermost electron orbitals, which are highly unstable and highly reactive), or as compounds with paired electrons, such as hydrogen peroxide (H2O2) or singlet oxygen. Reactive oxygen species have the advantage of having a biological defense function that sterilizes bacteria in the physiological system, but generally have a harmful effect that causes diseases by causing oxidation in the body. These reactive oxygen species attack biological molecules, damage cells and tissues, and there are reports that they cause various diseases related to aging and various adult diseases.

[0008] Research has continued to develop substances that inhibit skin aging caused by the various factors mentioned above, improve wrinkles, elasticity, and skin troubles, and possess antioxidant properties. Substances with beneficial effects on the skin are widely distributed throughout nature, and plant-derived natural substances have been primarily used as ingredients in foods, cosmetics, and pharmaceuticals. However, these natural substances are not very effective, requiring large quantities to achieve significant results. This has led to concerns about toxicity and increased costs.

[0009] To address the problems of these natural substances, the development of chemically synthesized substances has continued. While these chemically synthesized substances offer the advantage of being significantly more effective than natural substances, even in small amounts, their use is limited due to the potentially fatal side effects they can cause in the human body, both major and minor.

[0010] Accordingly, there is a need to develop new substances that are derived from natural products, have guaranteed stability, and exhibit excellent skin improvement effects.

[0011] The problem to be solved by the present disclosure is to improve the problems of conventional skin improvement agents, such as side effects or precautions for use, and to provide a skin improvement composition that is safe for the human body and has an excellent effect on improving skin barrier or elasticity, without the disadvantages of weak effects of skin improvement agents.

[0012] To address the above-described challenges, the inventors of the present disclosure have conducted extensive research and have discovered that a combination of PDRN (polydeoxyribonucleotide) and one or more of troxerutin, panthenol, arachidyl glucoside, and Irish moss extract (Chondrus crispus extract) promotes improvement in skin barrier and elasticity. In particular, they have surprisingly discovered that a remarkable synergistic effect in improving skin barrier and elasticity occurs when the ingredients are combined as described above, compared to when the ingredients are used individually, thereby completing the present invention.

[0013] The present disclosure provides a composition for improving skin barrier or elasticity, comprising as an active ingredient at least one selected from the group consisting of PDRN, troxerutin, panthenol, arachidyl glucoside, and Irish moss extract.

[0014] In one aspect of the present disclosure, the PDRN may be a transparent liquid substance made of DNA fragments. The PDRN may be extracted from various types of animals or plants, and may be obtained, for example, from the testis of salmonids, gardenia mushrooms, or oats. In one aspect of the present disclosure, the PDRN may be obtained by filtration through a filter having a pore size of 0.3 to 1 μm, preferably 0.4 to 0.5 μm, during extraction. In one aspect of the present disclosure, the PDRN may have an average molecular weight of 5 to 4000 kDa, preferably 20 to 2000 kDa, and more preferably 50 to 1000 kDa. In one aspect of the present disclosure, the composition may include a DNA fragment referred to as a polynucleotide (PN), and a polynucleotide having the same extraction conditions and average molecular weight as the PDRN may be used.

[0015] In one aspect of the present disclosure, troxerutin, also known as vitamin P4, has a chemical name of 3',4',7'-Tri[O-(2-hydroxyethyl)]rutin, and is a natural flavonoid obtained from Sophora Japonica. Troxerutin is a stable bioflavonoid and is known to have anti-inflammatory effects by inhibiting lipoxygenase and suppressing prostaglandin formation. In addition, troxerutin can stabilize the skin by regulating capillary resistance to promote healthy blood and lymph microcirculation. In addition, troxerutin has the effect of protecting skin cells from ultraviolet-induced cell death, restricted cell migration, growth arrest, and DNA damage in skin cells.

[0016] In one aspect of the present disclosure, panthenol is a precursor of vitamin B5, which is broken down in the body and converted to pantothenic acid. Panthenol is already known to have the effect of improving the skin's ability to retain moisture, and is therefore widely used in rash creams and ointments.

[0017] In one aspect of the present disclosure, the arachidyl glucoside is a substance obtained by the condensation reaction of arachidyl alcohol and glucose. The arachidyl glucoside helps soften and soften the skin, and helps stabilize the emulsion of other ingredients that are not mixed together in cosmetics.

[0018] In one aspect of the present disclosure, Irish moss (Chondrus crispus) is a seaweed belonging to the genus Carrageena of the family Crispus, also known as carraigin, and is a red algae that grows on rocky areas along the Atlantic coasts of Europe and North America. Irish moss is characterized by containing large amounts of MAA (Mycosporine-like Amino Acids) components such as Porphyra-334 and Palythene.

[0019] The Irish moss extract used in the present disclosure includes the extract itself and all formulations that can be formed using the extract, such as an extract obtained by extracting Irish moss, a diluted or concentrated extract, a dried product obtained by drying the extract, a conditioned or purified product of the extract, or a mixture thereof.

[0020] In the extraction of the above Irish moss, the extraction method is not particularly limited, and extraction can be performed according to a method commonly used in the relevant technical field. Non-limiting examples of the above extraction method include hot water extraction, ultrasonic extraction, filtration, or reflux extraction, and these may be performed alone or in combination of two or more extraction methods.

[0021] The type of extraction solvent used to extract the Irish moss is not particularly limited, and any solvent known in the art can be used. Non-limiting examples of the extraction solvent include water; lower alcohols having 1 to 4 carbon atoms, such as methanol, ethanol, propyl alcohol, or butyl alcohol; polyhydric alcohols, such as glycerin, butylene glycol, or propylene glycol; and hydrocarbon solvents, such as methyl acetate, ethyl acetate, acetone, benzene, hexane, diethyl ether, or dichloromethane; or mixtures thereof. Preferably, water, lower alcohols, 1,3-butylene glycol, and ethyl acetate can be used alone or in combination of two or more.

[0022] In one aspect of the present disclosure, the Irish moss extract may be used as is after filtering, for example, filtering out particles using nylon or the like, or filtering using a cryofiltration method, etc. to remove floating solid particles, or after drying using freeze-drying, hot air drying, spray drying, etc.

[0023] In one aspect of the present disclosure, the term "skin barrier" refers to a physical, chemical, or physiological barrier formed by the skin to prevent the intrusion of external substances, such as pathogens, and the outflow of substances to the outside, while simultaneously preventing chemical or physical damage and damage to moisture or minerals. Furthermore, the term "skin barrier improvement" may refer to chemically or biologically restoring a damaged skin barrier, thereby improving the skin's function as a barrier so that the skin can effectively prevent the intrusion of external substances or the outflow of substances to the outside. This is distinct from skin moisturizing, which simply directly replenishes moisture in the skin or physically prevents moisture loss.

[0024] In addition, the term "improvement in skin elasticity" may mean increasing skin elasticity, inhibiting collagen-decomposing enzymes and promoting collagen production to suppress or inhibit loss of skin elasticity, or alleviating already reduced elasticity. In addition, the "improvement in skin barrier or elasticity" may be achieved by strengthening the skeleton of skin cells by increasing the production of fibronectin and collagen, and this may be achieved by increasing the expression levels of the fibronectin gene (FN1) and the collagen gene (COL1A1) (see Experimental Example 2).

[0025] In one aspect of the present disclosure, the active ingredient may be included in an amount of 0.00001 to 50 wt%, preferably 0.0001 to 0.1 wt%, based on the total weight of the composition. When the content of the active ingredient is used within the above range, the effect may be better. In addition, each of the PDRN, troxerutin, panthenol, arachidyl glucoside, or Irish moss extract may be included in an amount of 0.00001 to 50 wt%, preferably 0.0001 to 0.1 wt%, based on the total weight of the composition. When each of the above components is included in the composition within the above weight ratio range, the skin barrier or elasticity improvement effect can be significantly and safely exhibited on the human body.

[0026] In one aspect of the present disclosure, the composition may include PDRN; and at least one selected from the group consisting of troxerutin, panthenol, arachidyl glucoside, and Irish moss extract at a weight ratio of 1:0.1 to 10, preferably 1:0.2 to 5, more preferably 1:0.3 to 3, and even more preferably 1:0.5 to 1.5 (PDRN: at least one selected from the group consisting of troxerutin, panthenol, arachidyl glucoside, and Irish moss extract). When the active ingredients are included at a specific weight ratio as described above, the synergistic effect for improving skin barrier or elasticity can be further enhanced.

[0027] In one aspect of the present disclosure, the composition may include PDRN and arachidyl glucoside as active ingredients, and may include PDRN and arachidyl glucoside in a weight ratio (PDRN: arachidyl glucoside) of 1:1 to 10, preferably 1:2 to 7, and more preferably 1:3 to 5. When PDRN and arachidyl glucoside are included in a specific weight ratio as described above, the synergistic effect on improving skin barrier or elasticity may be further enhanced.

[0028] In one aspect of the present disclosure, the composition may include PDRN, troxerutine, and arachidyl glucoside as active ingredients, in which case the synergistic effect on improving skin barrier or elasticity is more excellent. Preferably, the composition may include PDRN, troxerutine, and arachidyl glucoside in a weight ratio of 1:0.1 to 5:0.1 to 10, preferably 1:0.3 to 3:1 to 8, and more preferably 1:0.5 to 1.5:3 to 6 (PDRN:troxerutine:arachidyl glucoside). When PDRN, troxerutine, and arachidyl glucoside are included in a specific weight ratio as described above, the synergistic effect on improving skin barrier or elasticity can be further enhanced.

[0029] In addition, the present disclosure provides a cosmetic composition for improving skin barrier or elasticity, comprising as an active ingredient at least one selected from the group consisting of PDRN, troxerutin, panthenol, arachidyl glucoside, and Irish moss extract.

[0030] In one aspect of the present disclosure, the cosmetic composition may include conventional adjuvants in the cosmetic-related technical field, such as fatty substances, organic solvents, solubilizers, thickeners, gelling agents, emollients, antioxidants, suspending agents, stabilizers, foaming agents, fragrances, surfactants, water, ionic or nonionic emulsifiers, fillers, sequestering agents, chelating agents, preservatives, vitamins, blocking agents, humectants, essential oils, dyes, pigments, hydrophilic or lipophilic active agents, or lipid vesicles, and may also include any other ingredients conventionally used in cosmetics.

[0031] In one aspect of the present disclosure, the formulation of the cosmetic composition may be prepared as, for example, a solution, an emulsion, a suspension, a paste, a cream, a lotion, a gel, a powder, a spray, a surfactant-containing cleansing, an oil, a soap, a liquid cleanser, a bath agent, a foundation, a makeup base, an essence, a toner, a foam, a pack, an emollient, a sunscreen cream, or a sun oil. Preferably, the formulation of the cosmetic composition may be prepared as, for example, a skin ointment, an emollient toner, a nourishing toner, a nourishing cream, a massage cream, an essence, a pack, an emulsion, or an oil gel.

[0032] In addition, the present disclosure provides a composition for external application for skin for improving skin barrier or elasticity, comprising as an active ingredient at least one selected from the group consisting of PDRN, troxerutin, panthenol, arachidyl glucoside, and Irish moss extract.

[0033] In one aspect of the present disclosure, the external skin composition may refer to a solid, semi-solid, or liquid external preparation that can be easily applied to the skin by mixing an active ingredient with various bases such as oils, petrolatum, lanolin, or glycerol. The external formulation is not particularly limited, but may be in the form of a powder, gel, ointment, cream, liquid, or aerosol.

[0034] In one aspect of the present disclosure, the composition for improving skin barrier or elasticity can be applied to the face or other body parts through a transdermal administration method such as direct application or spraying on the skin. The terms "administration" or "application" refer to introducing the composition of the present disclosure to the skin by any suitable method. The composition can be administered through any common route as long as it can reach the target tissue, and can be administered transdermally, preferably topically. The frequency of administration or application of the composition can be appropriately determined according to the user's needs. The amount of the composition used can be appropriately adjusted according to individual differences such as age or skin condition or the formulation, and can typically be applied to the skin in an appropriate amount once or several times a day for one week to several months. In an example of the present disclosure, the composition for improving skin barrier or elasticity was used twice a day, in the morning and evening, for two months, and as a result, a significant effect of improving skin barrier or elasticity was observed (Experimental Example 4).

[0035] In one aspect of the present disclosure, the composition for improving skin barrier or elasticity can be applied in any form or through a carrier. For example, the composition can be applied in the form of a conventional solution, dispersion, emulsion, paste, or powder, and can be used individually or as a premix. Furthermore, the composition can be applied through a vehicle such as a macro-, micro-, or nano-sized capsule, sphere, liposome, or oleosome, and can be applied through a vector such as a nano-sized particle or sponge, or a nano-emulsion. Furthermore, the composition can be applied by absorption onto an organic polymer powder, talc, bentonite, or other inorganic / organic support. Furthermore, the composition can be adsorbed or absorbed into any type of fabric, natural or synthetic fiber, wool, or clothing or underwear that comes into contact with the skin through a vehicle such as a macro-, micro-, or nano-sized particle or capsule. In this manner, the composition can be adsorbed or absorbed into the fabric or clothing, etc., and continuously topically delivered to the skin through contact between the skin and the fabric.

[0036] In addition, the present disclosure provides a composition comprising PDRN; and at least one selected from the group consisting of troxerutin, panthenol, arachidyl glucoside, and Irish moss extract for use in improving skin barrier or elasticity.

[0037] In addition, the present disclosure provides a method for preparing a composition for improving skin barrier or elasticity, comprising the step of mixing PDRN; and at least one selected from the group consisting of troxerutin, panthenol, arachidyl glucoside, and Irish moss extract.

[0038] In addition, the present disclosure provides a method for improving skin barrier or elasticity, comprising applying to the skin a composition comprising, as an active ingredient, at least one selected from the group consisting of PDRN; and troxerutin, panthenol, arachidyl glucoside, and Irish moss extract.

[0039] In one aspect of the present disclosure, the method for improving skin barrier or elasticity may include applying the composition to the skin so that the dosage of the active ingredient in the composition is 1 to 1000 mg / L, preferably 10 to 500 mg / L. In addition, the method may include applying the composition to the skin for more than a week, for example, for 1 day to 6 months, preferably for 1 week to 4 months, but the maximum application period is not limited. In addition, the method may include applying the composition to the skin 1 to 6 times a day, preferably 1 to 3 times, for example, for twice a day, in the morning and evening.

[0040] All ingredients described in the present disclosure preferably do not exceed the maximum usage levels specified in relevant laws and regulations of Korea, China, the United States, Europe, Japan, etc. (e.g., Regulations on Cosmetic Safety Standards (Korea) or Cosmetic Safety Technical Standards (China), etc.). That is, preferably, the cosmetic or skin external preparation composition according to the present disclosure includes the ingredients according to the present disclosure within the content limits permitted by relevant laws and regulations of each country.

[0041] The composition for improving skin barrier or elasticity of the present disclosure exhibits a remarkably excellent synergistic effect in improving skin barrier or elasticity through the combination of specific active ingredients. Accordingly, the composition for improving skin barrier or elasticity of the present disclosure can be effectively utilized as a functional composition in cosmetics or external skin preparations targeting skin tissue.

[0042] Hereinafter, the present invention will be described in detail, using examples and the like, to aid understanding. However, the examples according to the present invention may be modified in various different forms, and the scope of the present invention should not be construed as being limited to the following examples. The examples of the present invention are provided to more fully explain the present invention to those of average skill in the art.

[0043]

[0044] Preparation of cosmetic compositions for improving skin barrier or elasticity of Examples 1 to 7

[0045] A skin tonic composition was prepared using PDRN, troxerutin, panthenol, arachidyl glucoside, and Irish moss extract ingredients in a conventional manner according to the recipe described in Table 1 below. PDRN used in the examples below was obtained by fragmenting salmon DNA and filtering it through a 0.5 μm filter, and Irish moss extract was obtained by hot water extraction at 100°C. Troxerutin and panthenol were purchased from conventional raw material suppliers and used.

[0046] Comparative examples of weight ratio of ingredients (%) Example 1 Example 2 Example 3 Example 4 Example 5 Example 6 Example 7 Cetostearyl alcohol dichloride stearyl triethyl ammonium 2-hydroxyethyl cellulose 0.5 PDRN-0.010.0050.0050.0050.0050.0020.0016 Troxerutin--0.005---0.0016 Panthenol---0.005--Arachidyl glucoside----0.005-0.0080.0068 Irish moss extract-----0.005 Flavoring and coloring agent Appropriate amount of purified water remaining (Total 100)

[0047]

[0048] Experimental Example 1: Effect of promoting fibroblast activity

[0049] Human fibroblasts were purchased from Promocell. The fibroblasts were cultured in DMEM (Hyclone Inc., UT, USA) containing 5% fetal bovine serum (FBS; Gibco, NY, USA), 100 units / mL penicillin, and 100 μg / mL streptomycin at 37°C and 5% CO2. 3,000 cells / well of the cultured fibroblasts were seeded into 96-well plates and cultured for 24 hours in a 0.1% serum environment. The cultured cells were treated with DMSO (vehicle) diluted 1:1000 in serum-free DMEM, which served as a control group, and those treated with 100 ng / mL Wnt3a served as a positive control. The cultured cells were treated with PDRN, troxerutin, panthenol, arachidyl glucoside, and Irish moss extract at the concentrations listed in Table 2, respectively, and cultured for one day. After culture, the degree of cell activity enhancement was evaluated using the CCK method. CCK-8 was added to the culture medium at a ratio of 1:10 and cultured for 1 hour. After 1 hour, the absorbance of each well was measured at 450 nm. All experiments were repeated three times, and the average absorbance values ​​were calculated. The results are expressed as a percentage of the treatment group compared to the control group, which was set at 100.

[0050] Material concentration Fibroblast cell activity NT (untreated group) - 100.0% Wnt3a 100ng / ml 143.1% PDRN 100㎍ / ml 124.1% Troxerutin 100㎍ / ml 102.0% Panthenol 100㎍ / ml 130.2% Arachidyl glucoside 100㎍ / ml 98.8% Irish moss extract 100㎍ / ml 108.2% PDRN + Troxerutin 50㎍ / ml + 50㎍ / ml 138.2% PDRN + Panthenol 50㎍ / ml + 50㎍ / ml 144.3% PDRN + Irish moss extract 50㎍ / ml + 50㎍ / ml 133.0% PDRN + Arachidyl glucoside 50㎍ / ml + 50㎍ / ml 130.1% PDRN + Arachidyl glucoside 20㎍ / ml + 80㎍ / ㎖ 142.7% PDRN + troxerutine + arachidyl glucoside 16㎍ / ㎖ + 16㎍ / ㎖ + 68㎍ / ㎖ 151.3%

[0051] As shown in the results shown in Table 2 above, it was confirmed that when PDRN and one or more selected from the group consisting of troxerutin, panthenol, arachidyl glucoside, and Irish moss extract were combined and treated, a remarkable synergistic effect was observed in enhancing fibroblast activity. This indicates that the composition of the present disclosure has a remarkably excellent effect in improving skin barrier and skin elasticity by enhancing fibroblast activity.

[0052]

[0053] Experimental Example 2: Gene regulation effects on improving skin barrier or elasticity in fibroblasts.

[0054] Fibronectin and collagen, which constitute the cytoskeleton, play an important role in skin barrier and elasticity. The FN1 and COL1A1 genes encode one type of fibronectin or collagen, and are known to play an important role in skin barrier and elasticity. Therefore, the effects of PDRN, troxerutin, panthenol, arachidyl glucoside, Irish moss extract, or a mixture thereof of the present disclosure on the expression of these genes in fibroblasts were investigated.

[0055] 1*10 breast papilla cells 5 After seeding cells / well in each well of a 6-well plate, PDRN, troxerutin, panthenol, arachidyl glucoside, Irish moss extract, or a mixture thereof were treated at 100 μg / ml each as described in Table 4 below. The expression levels of FN1 and Col1A1 were investigated using real-time PCR technique, and the results are shown in Table 4 below. Taqman used in the real-time PCR ® The probes (Thermo Fisher, Massachusetts, USA) are as described in Table 3 below.

[0056] Gene Taqman ® Probe Assay IDFN1Hs01549976_m1COL1A1Hs00164004_m1

[0057] Substance concentration FN1 expression level COL1A1 expression level NT (untreated group) 100.0% 100.0% Wnt3a 100ng / ml 142.1% 152.1% PDRN 100㎍ / ㎖ 123.3% 132.0% Troxerutin 100㎍ / ㎖ 103.1% 105.1% Panthenol 100㎍ / ㎖ 133.0% 142.4% Irish moss extract 100㎍ / ㎖ 111.1% 109.4% Arachidyl glucoside 100㎍ / ㎖ 99.7% 100.2% PDRN + Troxerutin 50㎍ / ㎖ + 50㎍ / ㎖ 151.4% 144.0% PDRN + Panthenol 50㎍ / ㎖ + 50㎍ / ㎖ 147.2% 147.2% PDRN + Irish moss extract 50㎍ / ㎖ + 50㎍ / ㎖ 138.9% 140.1% PDRN + Arachidyl Glucoside 50㎍ / ㎖ + 50㎍ / ㎖ 134.5% 139.8% PDRN + Arachidyl Glucoside 20㎍ / ㎖ + 80㎍ / ㎖ 144.0% 151.2% PDRN + Troxerutin + Arachidyl Glucoside 16㎍ / ㎖ + 16㎍ / ㎖ + 68㎍ / ㎖ 156.8% 162.5%

[0058] As shown in the results shown in Table 4 above, it was confirmed that when PDRN and one or more selected from the group consisting of troxerutin, panthenol, arachidyl glucoside, and Irish moss extract were combined and treated, a remarkable synergistic effect was observed on the expression levels of the FN1 and COL1A1 genes. Through this, it can be seen that the composition of the present disclosure has a remarkable excellent effect on improving the skin barrier and skin elasticity by increasing the synthesis of fibronectin and collagen, which constitute the cytoskeleton.

[0059]

[0060] Experimental Example 3: Wound healing promotion effect in fibroblasts

[0061] Human fibroblasts were purchased from Promocell. The fibroblasts were cultured in DMEM (Hyclone Inc., UT, USA) containing 5% fetal bovine serum (FBS; Gibco, NY, USA), 100 units / mL penicillin, and 100 μg / mL streptomycin at 37°C and 5% CO2. 80,000 cells / well of the cultured fibroblasts were seeded into 6-well plates and cultured for 24 hours in a 0.1% serum environment. After a uniform wound was created between the plates using a metal tip, the cultured cells were treated with DMSO (vehicle) diluted 1:1000 in serum-free DMEM as a control, and 2 μg / mL of Wnt3a was treated as a positive control. In addition, as described in Table 5 below, PDRN, troxerutin, panthenol, arachidyl glucoside, Irish moss extract, or a mixture thereof were each treated and cultured for 1 day. The change in the wounded area of ​​the plate before and after culture was captured by obtaining images under a microscope at ×200 magnification and quantified using ImageJ. All experiments were repeated three times, and the average reduction in wound area was calculated. The results were expressed as a percentage of the treatment group compared to the control group, which was set at 100.

[0062] Substance concentration In-vitro wound healing effect NT (untreated group) 100.0% Wnt3a 100 ng / ml 180.0% PDRN 100 ppm 164.4% Troxerutin 100 ppm 105.0% Panthenol 100 ppm 143.7% Irish moss extract 100 ppm 112.5% ​​PDRN + Troxerutin 50 ppm + 50 ppm 214.4% PDRN + Panthenol 50 ppm + 50 ppm 231.7% PDRN + Irish moss extract 50 ppm + 50 ppm 194.2% PDRN + Arachidyl glucoside 20 ppm + 80 ppm 224.3% PDRN + Troxerutin + Arachidyl glucoside 16 ppm + 16 ppm + 68 ppm 286.1%

[0063] As shown in the results shown in Table 5 above, it was confirmed that a significant synergistic effect on in vitro wound healing was observed when PDRN was combined with one or more selected from the group consisting of troxerutin, panthenol, arachidyl glucoside, and Irish moss extract. This indicates that the composition of the present disclosure significantly enhances wound healing in fibroblasts, demonstrating a remarkable improvement in skin barrier and skin elasticity.

[0064]

[0065] Experimental Example 4: Confirming the effectiveness of a composition for improving skin barrier or elasticity.

[0066] The skin barrier or elasticity improvement effect of the composition for improving skin barrier or elasticity of the present disclosure was tested on a total of 35 men and women. Using the skin tonic compositions of Comparative Example 1 and Examples 1 to 7, the skin barrier or elasticity improvement effect test of the compositions was conducted for a total of 2 months.

[0067] The test sequence was divided into two periods: before and after use of the test product, with measurements taken two months later. Furthermore, during the human application period, all cosmetics containing active ingredients that could affect the skin barrier or elasticity were prohibited. Subjects were instructed to use the test product twice daily, in the morning and evening, for two months.

[0068] The skin barrier improvement effect was measured by waiting for 10 to 15 minutes under constant temperature and humidity conditions (25°C, 40% relative humidity) after washing the face, and then measuring the static state for 10 to 15 seconds using a Vapometer (EP1, Delfin Technologies Ltd, 70211 Kuopio, FINLAND) in std mode. The experiment was repeated three times, and the average value was calculated.

[0069] The improvement in skin elasticity was measured using a cutometer (Cutometer® dual MPA580 from Courage + Khazaka electronic GmbH), a device that measures skin elasticity using negative pressure. Skin elasticity was measured on the same forehead area of ​​the subjects before and after using the test product. The experiment was repeated three times, and the average value was calculated. The measurement results are shown in Table 6 below.

[0070] Treatment group Skin barrier Skin elasticity Skin barrier improvement rate (%) Skin elasticity improvement rate Comparative example 10.0% 0.0% Example 136.0% 28.1% Example 262.0% 47.7% Example 367.6% 47.2% Example 451.6% 39.5% Example 534.8% 37.5% Example 668.1% 45.9% Example 770.4% 51.0%

[0071] As shown in the results shown in Table 6 above, when PDRN and one or more selected from the group consisting of troxerutin, panthenol, arachidyl glucoside, and Irish moss extract were combined and applied to actual skin, a remarkable synergistic effect was observed in improving the skin barrier or elasticity. This demonstrates that the composition of the present disclosure can be very effectively used to improve the skin barrier or elasticity.

[0072] In this disclosure, the above examples were prepared as skin tonic formulations and their effects on improving skin barrier and elasticity were confirmed. However, these formulation examples are merely examples of the compositions for improving skin barrier or elasticity of the present disclosure, and it will be apparent to those skilled in the art that the scope of the compositions of the present disclosure is not limited to these formulations.

Claims

1. PDRN(polydeoxyribonucleotide); and A composition for improving skin barrier or elasticity, comprising at least one active ingredient selected from the group consisting of troxerutin, panthenol, arachidyl glucoside, and Irish moss extract (Chondrus crispus extract).

2. In the first paragraph, the PDRN is a DNA fragment extracted from the testis of salmonid fish, and the composition for improving skin barrier or elasticity has a molecular weight of 5 to 4000 kDa.

3. A composition for improving skin barrier or elasticity, wherein the effective ingredient is included in an amount of 0.00001 to 50 wt% based on the total weight of the composition in paragraph 1.

4. In the first paragraph, the composition comprises PDRN; and at least one selected from the group consisting of troxerutin, panthenol, arachidyl glucoside, and Irish moss extract at a weight ratio of 1:0.1 to 10 (PDRN: at least one selected from the group consisting of troxerutin, panthenol, arachidyl glucoside, and Irish moss extract). A composition for improving skin barrier or elasticity.

5. In the first paragraph, the composition comprises PDRN and arachidyl glucoside as active ingredients, and comprises PDRN and arachidyl glucoside in a weight ratio of 1:1 to 10 (PDRN: arachidyl glucoside) for improving skin barrier or elasticity.

6. In the first paragraph, the composition comprises PDRN, troxerutine and arachidyl glucoside as active ingredients, and comprises PDRN, troxerutine and arachidyl glucoside in a weight ratio of 1: 0.1 to 5: 0.1 to 10 (PDRN: troxerutine: arachidyl glucoside) for improving skin barrier or elasticity.

7. In the first paragraph, the composition is a composition for improving skin barrier or elasticity, which is a cosmetic or external skin agent.